Mutations that activate the EGFR gene, such as exon 19 deletions and exon 21 L858R point mutations, are found in approximately 15% of Caucasian patients and 50% of East-Asian patients with advanced NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.